Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.51 |
| ▸ | IGF1R | P08069 | 2/20 | 0.47 |
| ▸ | TTK | P33981 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 2/20 | 0.45 |
| ▸ | PRKDC | P78527 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781041 | 0.87 | BRD4 (0.63) | LRRK2PTK2IGF1RAURKAPLK1 | |
| SCHEMBL1782949 | 0.84 | TTK (0.66) | LRRK2PTK2TTKAURKACCNA2 | |
| SCHEMBL1782276 | 0.79 | EGFR (0.59) | LRRK2EGFRIGF1RTTKAURKA | |
| SCHEMBL1780091 | 0.79 | TTK (0.57) | EGFRPTK2IGF1RTTKAURKA | |
| SCHEMBL1781068 | 0.77 | TTK (0.76) | EGFRIGF1RTTKAURKACCNA2 | |
| SCHEMBL1782666 | 0.77 | EGFR (0.51) | LRRK2EGFRIGF1RTTKBRD4 | |
| SCHEMBL1780904 | 0.77 | EGFR (0.56) | LRRK2EGFRIGF1RTTKAURKA | |
| SCHEMBL1781156 | 0.77 | TTK (0.70) | EGFRIGF1RTTKAURKACCNA2 | |
| SCHEMBL1781289 | 0.74 | TTK (0.68) | LRRK2TTKAURKACCNA2CDK2 | |
| SCHEMBL1782281 | 0.74 | TTK (0.54) | LRRK2EGFRPTK2TTKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | LRRK2 840/4885EGFR 2420/4885PTK2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.